Printer Friendly

Somavert. (New & Approved: Albumin Cobalt Binding Test, Somavert).

(pegvisomant for injection, Pharmacia)

A growth hormone receptor antagonist for acromegaly, in people who have had an inadequate response to existing treatments (surgery, radiation treatment, and other medical therapies), or when these treatments are not appropriate. The first drug in this new class of drugs to be approved.

* Recommended Dosage: Subcutaneous 40-mg loading dose, followed by a 10-mg subcutaneous injection daily, adjusting dose based on serum insulin-like growth factor-I (IGF-I) levels, with dose not to exceed 30 mg a day.

* Special Considerations: Injection site reactions, sweating, headache, and fatigue were the most common side effects associated with treatment in trials. Monitor liver function for the first 6 months of therapy; in trials, two patients (fewer than 1%) had liver function tests above 10 times the upper limit of normal.

* Comment: The goal of treatment with Somavert, which blocks the effects of growth hormone, is to normalize serum levels of IGF-1, a biochemical measure of the severity of acromegaly. In patients with acromegaly, oversecretion of growth hormone, usually due to a pituitary tumor, results in overproduction of IGF-1. Treatment with Somavert normalized IGF-I levels in up to 92% of patients treated for a mean of 1 year in one study, and up to 82% of patients in a 12-week study. Compared with those on placebo, treatment was associated with improvements in signs and symptoms of the condition, such as ring size, soft tissue swelling, arthralgia, headache, perspiration, and fatigue.

Dr. Keith Friend, medical director at Pharmacia, said that there is "scientific interest" in Somavert for treating cancer and diabetic complications because growth hormone and IGF-I are involved in the pathogenesis of diabetic nephropathy and retinopathy, and in the promotion of tumor growth.
COPYRIGHT 2003 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Mechcatie, Elizabeth
Publication:OB GYN News
Date:May 15, 2003
Words:281
Previous Article:Albumin cobalt binding (ACB) test. (New & Approved: Albumin Cobalt Binding Test, Somavert).
Next Article:CV risk may warrant oral glucose tolerance test. (Type Diabetes).


Related Articles
Study in The New England Journal of Medicine Shows Investigational Drug May Offer Hope For Treatment of Debilitating Hormone Disease.
STUDY IN THE NEW ENGLAND JOURNAL OF MEDICINE SHOWS INVESTIGATIONAL DRUG MAY OFFER HOPE FOR TREATMENT OF DEBILITATING HORMONE DISEASE.
Pharmacia's Xalatan Becomes the Number-One Selling Glaucoma Treatment in Japan.
Albumin cobalt binding (ACB) test. (New & Approved: Albumin Cobalt Binding Test, Somavert).
New & approved: Albumin Cobalt Binding Test, Somavert. (Rx).
U.S. Food and Drug Administration Approves SOMAVERT(R) for the Treatment Of Acromegaly; First in a New Class of Medicines Treats Debilitating Hormone...
European Commission Approves SOMAVERT(R) for the Treatment of Acromegaly.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters